Chronic Lymphocytic Leukemia | Specialty

Dr. Byrd on Ibrutinib Versus Ofatumumab in CLL

June 1st 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial

May 31st 2014

Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.

Emerging Treatments and Trends in Hematologic Malignancies: A Q&A With Anas Younes, MD

April 30th 2014

At the 18th Annual International Congress on Hematologic Malignancies, Anas Younes, MD, sat down with Oncology & Biotech News to discuss trends in the management of hematologic malignances.

FDA Approves First-Line Ofatumumab for Fludarabine-Ineligible Patients With CLL

April 17th 2014

The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.

Dr. Wierda on Treating CLL Patients with 17p Deletion

April 16th 2014

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with CLL who harbor the 17p deletion.

Dr. Ferrajoli on Managing CLL in Elderly Patients

April 15th 2014

Alessandra Ferrajoli, MD, from The University of Texas MD Anderson Cancer Center, discusses managing chronic lymphocytic leukemia (CLL) in elderly patients.

Dr. Flynn on CDK Inhibitors for the Treatment of CLL

April 7th 2014

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents

April 4th 2014

The approval of the first small-molecule, targeted therapy for patients with chronic lymphocytic leukemia (CLL) launches a new era that promises to transform management of the disease, yet significant challenges in translating research advances into improvements in long-term outcomes remain

Dr. Brentjens on Challenges of CAR-Modified T Cells

March 31st 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Obinutuzumab Gains Role in CLL Guidelines

March 25th 2014

Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease.

Gilead Sciences Moves Ahead on Idelalisib Filings

March 24th 2014

Founded in 1987, Gilead Sciences made a name for itself in 1996, when it launched Vistide, a treatment for cytomegalovirus retinitis in patients with AIDS.

Dr. Ferrajoli on Individualized Treatment of CLL

March 21st 2014

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses individualizing the treatment of chronic lymphocytic leukemia (CLL).

Dr. Wierda on the Treatment of Elderly CLL Patients

March 12th 2014

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment recommendations for patients with CLL.

Ibrutinib Represents "Transformative" Approach in CLL Treatment

March 11th 2014

Jennifer R. Brown, MD, PhD, and John Byrd, MD, are leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

Success of First BTK Inhibitor Opens New Options in B-Cell Malignancies

March 3rd 2014

A greater understanding of the molecular mechanisms underlying lymphoid malignancies has fostered the development of targeted therapies, including those aimed at B-cell signaling pathways.

Dr. Ferrajoli on the FDA Approval of Ibrutinib in CLL

February 17th 2014

Alessandra Ferrajoli, MD, discusses the recent approval of ibrutinib for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.

FDA Approves Ibrutinib for Chronic Lymphocytic Leukemia

February 12th 2014

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy.

Six Targeted Agents for CLL Command Spotlight at ASH

February 10th 2014

A crop of targeted agents have demonstrated promising results in fighting chronic lymphocytic leukemia (CLL), suggesting that a range of emerging therapies and drug combinations may be more effective and better tolerated than standard chemotherapy

Dr. Brentjens on CD19-Targeted T Cells in Leukemia

February 7th 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.

Changing Therapeutic Landscape in ALL, CLL, and NHL

January 22nd 2014